Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV

Vaccines, Free Full-Text

Race for a Coronavirus Vaccine

Immunogenicity of a DNA vaccine candidate for COVID-19

Inovio Pharmaceuticals, Inc. - INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet's EClinicalMedicine

Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines

Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India - eClinicalMedicine

Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model

Frontiers COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations

A brief review on DNA vaccines in the era of COVID-19

DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice

Advances in the design and development of SARS-CoV-2 vaccines, Military Medical Research

Phase 2 trial shows INO-4800 SARS-CoV-2 DNA vaccine safe and tolerable in adults